Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Bexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™

Bexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™

  • Post published:January 20, 2023
  • Post category:Press Release
Read more about the article Bexson Biomedical and Stevanato Group Awarded PDA Drug Delivery Innovation Award

Bexson Biomedical and Stevanato Group Awarded PDA Drug Delivery Innovation Award

  • Post published:October 20, 2022
  • Post category:Press Release
Read more about the article Bexson Biomedical Announces Renowned Scientist, Engineer and Inventor, Robert S. Langer ScD, Joins Its Scientific Advisory Board

Bexson Biomedical Announces Renowned Scientist, Engineer and Inventor, Robert S. Langer ScD, Joins Its Scientific Advisory Board

  • Post published:September 20, 2022
  • Post category:Press Release
Read more about the article Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SEVALENT™

Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SEVALENT™

  • Post published:September 15, 2022
  • Post category:Press Release
Read more about the article Bexson Biomedical Announces Participation in the Jeffries Innovation in Mental Health Summit

Bexson Biomedical Announces Participation in the Jeffries Innovation in Mental Health Summit

  • Post published:September 9, 2022
  • Post category:Press Release
Read more about the article Bexson Biomedical to present at the H.C. Wainwright and Beryl Elites Conferences

Bexson Biomedical to present at the H.C. Wainwright and Beryl Elites Conferences

  • Post published:June 17, 2022
  • Post category:Press Release
Read more about the article Bexson Biomedical Launches New Project, Applying Subcutaneous Delivery Technology To Multiple Psychedelic Compounds For Therapeutic Use

Bexson Biomedical Launches New Project, Applying Subcutaneous Delivery Technology To Multiple Psychedelic Compounds For Therapeutic Use

  • Post published:August 12, 2021
  • Post category:Press Release
Read more about the article Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation

Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation

  • Post published:April 29, 2021
  • Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More